Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity
Drug Discovery Today, ISSN: 1359-6446, Vol: 8, Issue: 20, Page: 934-943
2003
- 243Citations
- 239Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations243
- Citation Indexes242
- 242
- CrossRef203
- Patent Family Citations1
- Patent Families1
- Captures239
- Readers239
- 239
Review Description
Inactivated vaccines require adjuvants to stimulate an immune response. The choice of adjuvant or immune enhancer determines whether the immune response is effective, ineffective or damaging. Accordingly, there is a need for new adjuvants that stimulate the appropriate immunity, for example, T cell immunity for intracellular pathogens and cancer vaccines. In several adjuvants, the identification of chemical groups that interact with specific cell toll-like receptors (innate immunity) or receptors for co-stimulatory ligands (adaptive immunity), has enabled the establishment of structure–function relationships that are useful in the design of new adjuvants. Because of the crucial immunomodulating role of adjuvants, sub-unit vaccine development will remain dependent on new adjuvants.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1359644603028642; http://dx.doi.org/10.1016/s1359-6446(03)02864-2; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0141889064&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/14554157; http://linkinghub.elsevier.com/retrieve/pii/S1359644603028642; http://api.elsevier.com/content/article/PII:S1359644603028642?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1359644603028642?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1359644603028642; http://dx.doi.org/10.1016/s1359-6446%2803%2902864-2; https://dx.doi.org/10.1016/s1359-6446%2803%2902864-2
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know